INDIANAPOLIS, Feb. 4, 2021 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) will conduct a webcast on Monday, March 15, 2021 to provide an update on
its Alzheimer's disease program and discuss results from the Phase
2 TRAILBLAZER-ALZ study for donanemab being presented at the
15th International Conference on Alzheimer's and Parkinson's
Diseases (AD/PD). The webcast will begin at 10:30 a.m. Eastern Time.
Investors, media and the general public can access a live
webcast of the conference call through a link that will be posted
on Lilly's website at
https://investor.lilly.com/webcasts-and-presentations. A replay
will also be available on the website following the conference
call.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to create
medicines that make life better for people around the world. We
were founded more than a century ago by a man committed to creating
high-quality medicines that meet real needs, and today we remain
true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to
those who need them, improve the understanding and management of
disease, and give back to communities through philanthropy and
volunteerism. To learn more about Lilly, please visit us at
www.lilly.com. F-LLY
Refer
to:
|
Mark Taylor;
mark.taylor@lilly.com; (317) 276-5795 (Media)
|
|
Kevin Hern;
hern_kevin_r@lilly.com; (317) 277-1838 (Investors)
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lilly-announces-webcast-to-provide-alzheimers-disease-update-at-adpd-conference-301222615.html
SOURCE Eli Lilly and Company